SANITAS
Pioneering sustainable solutions against Willis-Ekbom Disease.
About our project
Project “Cephyra” is an innovative life sciences initiative dedicated to redefining care for individuals living with Willis-Ekbom Disease (WED). Grounded in science and driven by personalization, Cephyra offers a comprehensive, data-informed approach that goes beyond traditional symptom management to address the root causes of WED.
By combining at-home biomarker testing, expert coaching, AI-driven insights, and proprietary wearables like Cephyra Flow & Move, we deliver a care model tailored to each person’s unique biology and lifestyle. From personalised nutrition and supplement plans to guided movement programs, mYCephyra supports holistic, long-term relief—empowering individuals to reclaim comfort, mobility, and quality of life.
Why co-invest in “Cephyra”?
Aligned with Healthcare & Longevity Trends
Global health trends are shifting toward personalized medicine, digital health, and longevity-focused solutions—areas where mYCephyra is strategically positioned. Our model directly supports healthcare innovation priorities across Europe and beyond, tapping into the growing demand for individualized, non-pharmaceutical interventions.
Science-Driven, Personalized Healthcare Innovation
Cephyra is pioneering a personalized, data-led approach to managing Willis-Ekbom Disease (WED), a condition often overlooked in traditional medicine. By integrating AI-driven insights, at-home biomarker testing, and proprietary wearable technology, Cephyra offers a holistic care model with the potential to transform chronic disease management.
Robust Impact & ESG Credentials
Cephyra emphasizes sustainability in healthcare, with a focus on preventive, non-invasive care that reduces long-term dependency on medications. Our commitment to ethical health innovation, data privacy, and community support aligns with global ESG standards—positioning us as a responsible, forward-thinking investment in the life sciences sector.